Enanta Pharmaceuticals Inc Submits Form 144 Filing – What You Need to Know
Enanta Pharmaceuticals Inc, a biotechnology company specializing in the development of small molecule drugs for viral infections and liver diseases, has filed a Form 144 with the Securities and Exchange Commission. This filing indicates that certain shareholders, affiliates, or insiders of the company are planning to sell shares. Form 144 is required when insiders of a company plan to sell their shares and serves as a notice of their intent to sell within a specific timeframe.
Enanta Pharmaceuticals Inc, based in Watertown, Massachusetts, has a focus on developing novel treatments for hepatitis B and respiratory syncytial virus (RSV). The company’s pipeline includes a range of innovative drug candidates targeting these diseases, with several in various stages of clinical development. Enanta Pharmaceuticals Inc’s dedication to advancing therapies for infectious diseases makes them a key player in the biotechnology industry.
For more information about Enanta Pharmaceuticals Inc and its groundbreaking work in developing treatments for viral infections and liver diseases, please visit their official website at Enanta Pharmaceuticals Inc.
Read More:
Enanta Pharmaceuticals Inc Submits SEC Filing 144 – Key Updates Revealed
